Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGalliford Try Regulatory News (GFRD)

Share Price Information for Galliford Try (GFRD)

Share Price is delayed by 15 minutes
Get Live Data
522.00    -3.00 (-0.57%)
Bid:
524.00
Ask:
526.00
Spread: 2.00 (0.382%)
Market Cap: £512.62m
GFRD Live PriceLast checked at - London Stock Exchange

Intraday Galliford Try Share Chart

Contract

24 Sep 2019 07:00

RNS Number : 3679N
Galliford Try PLC
24 September 2019
 

GALLIFORD TRY APPOINTED TO HIGHWAYS PROJECTS VALUED AT £461M

 

Galliford Try plc, the leading housebuilding, regeneration and construction group, announces its Highways business has been appointed to new projects valued at a total of £461m.

 

The largest of the schemes is a series of five projects in the eastern region valued at £300m to upgrade the A47 between Great Yarmouth and Peterborough. Work includes dualling single carriageways, road widening and construction of new junctions, bridges and other structures. Start on site is anticipated to be in 2021/22.

 

The other major scheme with an overall value of £135m is located in the south-west region on the A303 between Sparkford and Ilchester in Somerset. Work includes dualling 5.6km of the existing single carriageway, three new junctions, two new structures and significant earthworks. Subject to planning consent, start on site is due next March with the new route open to traffic in 2023.

 

Both schemes have been awarded by Highways England under the new Regional Delivery Partnerships Framework. The appointments include an initial design phase before moving on to construction.

 

Additionally, Galliford Try has been awarded phase two of Grantham Southern Relief Road by Lincolnshire County Council. The £19m project will join the B1174 to the A1 via a grade separated junction.

 

Finally, Leicestershire County Council has awarded the business the £7m contract to carry out improvements to the A46 and A5630 at Anstey to increase capacity for a new housing and industrial development in the north-west of Leicester.

 

Graham Prothero, Chief Executive of Galliford Try plc, commented: "The Highways sector is a key strategic focus for our construction business as set out in our recent results, and we are delighted to have secured this high-quality pipeline of work. We have a strong working relationship with Highways England and the county councils involved and we look forward to delivering these much-needed infrastructure improvements alongside them."

 

 

For further enquiries please contact:

 

Galliford Try

 

Graham Prothero, Chief Executive 01895 855001

Andrew Duxbury, Finance Director

Kevin Corbett, General Counsel & Company Secretary

 

Galliford Try plc is a leading UK housebuilding, regeneration and construction group. It is listed on the London Stock Exchange and a member of the FTSE 250. Housebuilding - through our Linden Homes business - develops private and affordable homes in prime locations. Galliford Try Partnerships - our regeneration business - delivers mixed-tenure solutions working with housing association, local authority and private sector partners. Operating as Galliford Try and Morrison Construction, our Construction business carries out building and infrastructure with clients in the public, private and regulated sectors. At the end of the last financial year to 30 June 2019, the Group generated revenue of £2.8bn.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CNTDXLFLKKFFBBZ
Date   Source Headline
23rd Oct 202410:00 amRNSDirector/PDMR Shareholding
23rd Oct 20247:00 amRNSTransaction in Own Shares
22nd Oct 20247:00 amRNSTransaction in Own Shares
21st Oct 202411:30 amRNSAnnual Financial Report
16th Oct 20241:00 pmRNSDirector/PDMR Shareholding
15th Oct 20247:00 amRNSTransaction in Own Shares
14th Oct 20247:00 amRNSTransaction in Own Shares
11th Oct 202410:30 amRNSDirector/PDMR Shareholding
11th Oct 20247:00 amRNSTransaction in Own Shares
10th Oct 20247:00 amRNSTransaction in Own Shares
9th Oct 20247:00 amRNSTransaction in Own Shares
8th Oct 20243:50 pmRNSDirector/PDMR Shareholding
8th Oct 20243:45 pmRNSDirector/PDMR Shareholding
8th Oct 20243:45 pmRNSDirector/PDMR Shareholding
8th Oct 20247:00 amRNSTransaction in Own Shares
4th Oct 20245:25 pmRNSDirector/PDMR Shareholding
4th Oct 20247:00 amRNSTransaction in Own Shares
3rd Oct 20247:02 amRNSLaunch of Share Buyback Programme
3rd Oct 20247:00 amRNSFinal Results
30th Sep 20243:00 pmRNSTotal Voting Rights
24th Sep 20247:00 amRNSContract
23rd Sep 20247:00 amRNSContract
20th Sep 20248:44 amRNSNotification of Full Year Results
16th Sep 20247:01 amRNS2024 Full Year Results: Revised Publication Date
2nd Sep 20242:30 pmRNSDirector Declaration
2nd Sep 202410:30 amRNSTotal Voting Rights
27th Aug 20244:14 pmRNSBlock listing Interim Review
16th Aug 20249:30 amRNSContract
31st Jul 20244:00 pmRNSTotal Voting Rights
24th Jul 202410:30 amRNSDirector Declaration
23rd Jul 20247:00 amRNSContract
11th Jul 20247:00 amRNSTrading Statement
28th Jun 202411:00 amRNSTotal Voting Rights
13th Jun 20247:00 amRNSContract
31st May 20244:00 pmRNSTotal Voting Rights
31st May 20247:00 amRNSContract
23rd May 20247:00 amRNSCapital Markets Event
30th Apr 20244:00 pmRNSTotal Voting Rights
23rd Apr 20244:00 pmRNSDirector/PDMR Shareholding
10th Apr 20245:00 pmRNSHolding(s) in Company
5th Apr 202411:00 amRNSTotal Voting Rights
28th Mar 20247:00 amRNSDirectorate Change
8th Mar 20244:00 pmRNSDirector/PDMR Shareholding
6th Mar 20247:00 amRNSHalf-year Report
4th Mar 20244:00 pmRNSTotal Voting Rights
1st Mar 20247:00 amRNSDirectorate Change
26th Feb 20246:03 pmRNSBlock listing Interim Review
22nd Feb 20247:00 amRNSContract
17th Jan 20247:00 amRNSTrading Statement
30th Nov 20234:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.